Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
Curr Gastroenterol Rep
; 22(5): 24, 2020 Mar 19.
Article
en En
| MEDLINE
| ID: mdl-32193746
ABSTRACT
PURPOSE OF REVIEW The treatment of intestinal Behcet's disease (BD) is challenging, and one-third of patients require surgery due to failure of conventional therapies. Anti-tumor necrosis factor-α (TNF-α) and other new biologics have been actively investigated for managing intestinal BD. In this article, we review the updated experiences and up-to-date clinical data on anti-TNF-α and other biologics for the management of intestinal BD. RECENT FINDINGS:
Recent prospective studies have proved the efficacy and safety of infliximab and adalimumab for treating intestinal BD. Recent studies with other biologics such as anti-interleukin (IL)-1 (anakinra and canakinumab) and anti-IL-6 (tocilizumab) have shown promising results in patients with systemic, including intestinal, BD. Both infliximab and adalimumab can be useful in managing patients with intestinal BD, especially severe or refractory cases, with a similar efficacy and safety profile. More evidence for anakinra, canakinumab, tocilizumab, anti-IL-17 (secukinumab), and anti-IL-12/23 (ustekinumab) in intestinal BD is required.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Factores Biológicos
/
Síndrome de Behçet
/
Intestino Delgado
Tipo de estudio:
Observational_studies
Límite:
Humans
Idioma:
En
Revista:
Curr Gastroenterol Rep
Asunto de la revista:
GASTROENTEROLOGIA
Año:
2020
Tipo del documento:
Article